Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jan 6;6(1):4. doi: 10.1186/scrt538

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Ikhapoh et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Effect of antagonists for AT1R and AT2R on immunopositivity for endothelial cell markers. Mesenchymal stem cells (MSCs) were pretreated with either angiotensin receptor AT1R or AT2R inhibitor and then cultured with angiotensin II (Ang II) and vascular endothelial growth factor (VEGF-A). PD123319, an AT2R inhibitor, significantly reduced the expression of platelet endothelial cell adhesion molecule-1 (PECAM-1), von Willebrand factor (vWF) and vascular endothelial cadherin (VE-cadherin) (B), whereas there was a lesser effect of the AT1R inhibitor telmisartan (A). Bar diagram showing data from six individual experiments (C). Note that human umbilical vein endothelial cells were excluded from the statistical analyses. *P <0.05 vs. VEGF-A (2 ng/ml) plus Ang II (2 ng/ml)-treated MSCs. ^# P <0.05 telmisartan vs. PD123319-treated MSCs, n = 3.